Articles from Evofem Biosciences, Inc.

Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) has achieved an important milestone in its strategy to support long-term growth, enhance manufacturing flexibility, and reduce costs. Evofem has contracted with a second pharmaceutical manufacturer to produce PHEXX® (lactic acid, citric acid and potassium bitartrate), its hormone-free, on-demand prescription contraceptive vaginal gel. Subject to regulatory approval, the additional manufacturing source is expected to provide meaningful economic benefits while complementing Evofem's existing manufacturing operations.

Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) today announced the shipment of its 500,000th box of PHEXX® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel.

Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the first quarter ended March 31, 2026.

Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory).

Women’s health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025. Highlights include:

Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) today announced the launch of the Say Vagina Store, expanding its groundbreaking Say Vagina campaign aimed at normalizing accurate anatomical language and advancing education and autonomy in women’s health.